Part 7/7:
In the coming months, as details unfold regarding Allergan's generics sale and possible strategic directions, eyes will likely remain on Icahn. Market watchers are eager to discover whether he will enact his prowess in "activism" or take a quieter stance as a significant shareholder. The movement within Allergan could very well set the stage for the next chapter in corporate activism, driven by one of the industry's most noteworthy investors.